Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Gastrointest Cancer. 2010 Dec;41(4):217-20. doi: 10.1007/s12029-010-9163-y.

Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy?

Author information

  • 1Division of Transplantation, University of California, San Francisco, CA 94143, USA. parsia.vagefi@ucsfmedctr.org

Abstract

Hepatocellular carcinoma (HCC) remains a common cause of mortality worldwide. Liver transplantation has emerged as the optimal treatment for cirrhotic patients with HCC; however, the shortage of donor organs leaves waitlisted patients at risk for disease progression beyond transplant criteria. Prevention of waitlist dropout has fueled investigation into a wide array of locoregional therapies for the management of HCC in candidates awaiting liver transplantation. We present a patient with HCC who underwent treatment with sorafenib, which resulted in a remarkable reduction in tumor burden to allow for liver transplant listing.

PMID:
20443078
[PubMed - indexed for MEDLINE]
PMCID:
PMC2956885
Free PMC Article

Images from this publication.See all images (1)Free text

Fig. 1
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for PubMed Central
    Loading ...
    Write to the Help Desk